Three of the four partner centres sell genetic screening, and they are selling different things under one word. This page separates them, because a broad predictive-risk gene panel, a targeted hereditary-disease panel and a personal-traits report are not the same product and do not carry the same weight.
KMI, Medione and Hanaro. Severance publishes none.
Its COMMON DISEASES program names a genetic test of 11 types; its other targeted programs name five each, for cardio-cerebrovascular disease or for common cancers.
A partner centre's price for a disease-risk prediction panel, and the same again for a personal-traits report. (≈$224)
KMI COMMON DISEASES, where the 11-gene panel is part of the programme rather than an add-on. (≈$745)
One week is the earliest an imaging slot can be held, and there is no referral step before it.
English report in your hands in two weeks on average, one week at the soonest and three at the latest. You also get a consultation on preliminary findings on the day of the screening, before you leave.
Programme contents and prices from each partner centre's own foreigner-facing published list, read 2026-08-05: KMI Global and Hanaro Medical Foundation's English site. Standalone per-test prices are a Korean partner centre's 비급여 (non-covered) posting, the itemised list 의료법 제45조 requires a clinic to publish, read the same day. Scheduling and report turnaround confirmed 2026-08-06 and 2026-10-14 respectively (https://global.kmi.or.kr/examination/foreigner_examination; https://en-mobile.hanaromf.com/program/prog01/prog01_01.jsp), measured 2026-08-05. Dollar figures are converted from each centre's won price at ₩1,342 = $1 (open.er-api.com, 2026-09-13). The won figure is the price; the pairing moves with the rate.
A hereditary-cancer NGS panel sequences named genes for pathogenic variants and is the only one of the three with established clinical action attached. A disease-risk prediction panel scores common variants for conditions like diabetes or hypertension. A personal-traits report covers things like caffeine metabolism and is entertainment with a laboratory attached.
None of them tells you that you will develop a disease. A negative hereditary-cancer panel does not remove your risk, and a high polygenic score is not a diagnosis. None of them replaces a family history taken properly by a doctor.
Suits: People with a strong family history of cancer, cardiomyopathy or early stroke, for whom a hereditary panel can change surveillance. Hanaro is the partner that names its DNA panels individually, in the choices built into Silver and Gold and as add-ons, which is what makes them assessable.
Should not have it: Anyone hoping for reassurance. These panels are better at raising questions than settling them, and a result that needs genetic counselling to interpret is a result you should not receive in a language you do not read fluently or with nobody to discuss it with.
A tumour-marker blood panel measures something in your blood today. A genetic panel measures something that has been true since birth. The first can change next year; the second will not, which is why it is worth doing once and worth doing properly.
Not carried as a matter of course by the bands this site prices. At KMI, every targeted programme except WOMEN CANCER+ includes a genetic test of its own, and NOBLE includes one panel of your choosing. Medione's C. Premium Health Checkup includes predictive genetic testing and a personalised trait report, and Hanaro offers its DNA panels among the choices in Silver and Gold and sells them, with a pharmacogenomic panel, as add-ons. Which genes are actually sequenced differs between them, so ask for the gene list rather than the word.
